Insulin lispro in CSII: Results of a double-blind crossover study

Diabetes

Volumn 46, Issue 3, 1997, Pages 440-443

  Zinman, Bernard ^a   Tildesley, Hugh ^b   Chiasson, Jean Louis ^c   Tsui, Elaine ^a   Strack, Thomas ^d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031048313     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.46.3.440     Document Type: Article

References (27)

1. DiMarchi RD, Chance RE, Long HB, Shields JE, Slieker LJ: Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res 41 (Suppl. 2):93-96, 1994
2. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
3. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, DiVincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, Bolli GB: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 37:713-720, 1995
4. Slieker LJ, Sunder K: Modification in the 28-29 position of the insulin B-chain alters binding to the IGF-1 receptor with minimal effect on insulin receptor binding (Abstract). Diabetes 40 (Suppl. 1):168A, 1991
5. Zwickl CM, Smith HW, Zimmermann JL, Wierda D: Immunogenicity of human lyspro insulin compared to native-sequence human and purified porcine insulins in rhesus monkeys immunized over a 6 week period. Arznei Forsch 4:524-528, 1995
6. Anderson J, Symanowski S, Brunelle R: Safety of [Lys(B28), Pro(B29)] human insulin analog in long-term clinical trials (Abstract). Diabetes 43 (Suppl. 1):192A, 1994
7. Vignati L, Anderson J, Brunelle R: Efficacy of [Lys(B28), Pro(B29)] human insulin in a one year global randomized clinical trial (Abstract). Diabetes 43 (Suppl. 1):78A, 1994
8. Brunelle RL, Symanowski S, Anderson JH Jr, Vignati L: Less nocturnal hypoglycemia with insulin lispro in comparison with human regular insulin (Abstract). Diabetes 44 (Suppl. 1):111A, 1995
9. Brunelle RC, Andreson JH, Vignati L: Decreased rate of hypoglycemia in association with improved metabolic control with insulin lispro (Abstract). Diabetologia 37 (Suppl. 1):A78, 1994
10. The DCCT Research Group: Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 90:567-573, 1991
11. Zinman B: The physiological replacement of insulin: an elusive goal. N Engl J Med 321:363-370, 1989
12. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
13. Kang S, Brange J, Burch A, Volund A, Owens DR: Subcutaneous insulin absorption explained by insulin's physicochemical properties. Diabetes Care 14:942-947, 1991
14. Gulan M, Gottesman IS, Zinman B: Biosynthetic human insulin improves postprandial glucose excursions in type I diabetes. Ann Intern Med 107:506-509, 1987
15. Woodworth JR, Howey DC, Bowsher RR: Establishment of time-action proflies for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care 17:64-69, 1994
16. Gardner DF, Arakaki RF, Podet EJ, Nell LJ, Thomas JW, Field JB: The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessment using a glucose clamp technique. J Clin Endocrinol Metab 63:689-694, 1986
17. Rang S, Owens DR, Creagh FM, Williams S, Brange J, Peters JR: Effect of dimeric insulin analogue B10Asp on meal-related glucose rises in IDDMs (Abstract). Diabetic Med 6 (Suppl. 2):8A, 1990
18. Brange J, Owens D, Rang S, Volund A: Monomeric insulin and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
19. Heinemann L, Heise T, Jørgensen LN, Starke AAR: Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabetic Med 10:535-539, 1993
20. Nielsen FS, Jørgensen LN, Ipsen M, Voldsgaard AI, Parving HH: Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basis/bolus insulin regimen. Diabetologia 38:592-598, 1995
21. Lundemose AG, Danielsen G, Hansen BF, Sörensen A, Drejer K: Possible mechanisms behind the increased mitogenicity of insulin analogs (Abstract). Diabetes 44 (Suppl. 1):893, 1995
22. Berti L, Seffer E, Seipke G, Kroder G, Häring HU: Human insulin analog HOE901: characteristics of receptor binding and tyrosine kinase activation (Abstract). Diabetes 44 (Suppl. 1):243A, 1995
23. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
24. Anderson JH, Brunelle RL, Vignati L: Insulin lispro compared to regular insulin in a cross-over study involving 1037 patients with type I diabetes (Abstract). Diabetes 44 (Suppl. 1):228A, 1995
25. Vignati L, Brunelle RL: Treatment of 722 patients with type II diabetes with insulin lispro in a 6 month crossover study (Abstract). Diabetes 44 (Suppl. 1):229A, 1995
26. Wiefels K, Hübinger A, Dannehl K, Gries FA: Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp). Horm Metab Res 27:421-424, 1995
27. Pein P, Hinseimann C, Pfutener A, Dreyer M: Catheter disconnection in type-I diabetes treated with CSII: comparison of insulin lispro and human regular insulin. Diabetologia 39 (Suppl. 1):A847, 1996